Daron Evans Purchases 9,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 9,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $4.60 per share, for a total transaction of $41,400.00. Following the completion of the purchase, the chief financial officer now directly owns 140,900 shares in the company, valued at approximately $648,140. This trade represents a 6.82 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rezolute Stock Down 1.1 %

RZLT stock opened at $4.59 on Friday. The firm has a market capitalization of $265.96 million, a PE ratio of -3.61 and a beta of 1.01. Rezolute, Inc. has a twelve month low of $0.81 and a twelve month high of $6.19. The stock has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $4.78.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). On average, equities research analysts anticipate that Rezolute, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

RZLT has been the topic of a number of research reports. Guggenheim initiated coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price objective on the stock. BTIG Research boosted their price objective on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Wedbush restated an “outperform” rating and issued a $112.00 price objective on shares of Rezolute in a research note on Monday, November 4th. JMP Securities restated a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a research note on Friday, September 20th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Friday, November 8th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $24.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Jeppson Wealth Management LLC purchased a new position in shares of Rezolute during the second quarter worth about $45,000. MML Investors Services LLC purchased a new position in shares of Rezolute during the third quarter worth about $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Rezolute during the third quarter worth about $65,000. Virtu Financial LLC grew its holdings in shares of Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after purchasing an additional 9,551 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.